|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,880.00 JPY | +6.77% |
|
+7.88% | +22.62% |
| 03-04 | Irlab Working to Secure Funding for Phase 3 Study of Mesdopetam - fc | FW |
| 02-26 | Irlab Receives $3 Million Milestone Payment Following Dosing in Phase 1b Study | FW |
Business description: Otsuka Holdings Co., Ltd.
Number of employees: 37,758
Sales by Activity: Otsuka Holdings Co., Ltd.
| Fiscal Period: December | 2021 (JPY) | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) |
|---|---|---|---|---|---|
Pharmaceuticals | 978B | 1,138B | 1,364B | 1,629B | 1,744B |
Nutraceuticals | 377B | 437B | 483B | 557B | 578B |
Others | 150B | 169B | 134B | 114B | 116B |
Consumer Products | 31.92B | 35.88B | 37.07B | 33.76B | 34.63B |
Unallocated Adjustment | -37.79B | -42.01B | - | -3.63B | -3.57B |
Geographical breakdown of sales: Otsuka Holdings Co., Ltd.
| Fiscal Period: December | 2021 (JPY) | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) |
|---|---|---|---|---|---|
North America | 510B | 684B | 873B | 1,095B | 1,169B |
Japan | 647B | 655B | 671B | 700B | 718B |
Others | 185B | 227B | 256B | 292B | 297B |
EU | - | - | - | - | 285B |
Europe | 157B | 173B | 219B | 243B | - |
Executive Committee: Otsuka Holdings Co., Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Makoto Inoue
CEO | Chief Executive Officer | 67 | 31/12/2024 |
Yuko Makino
DFI | Director of Finance/CFO | 64 | 28/02/2018 |
Masanori Udagawa
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yoshiro Matsuo
PRN | Corporate Officer/Principal | 65 | 07/07/2008 |
Hiroki Nakayama
AUD | Comptroller/Controller/Auditor | - | - |
Composition of the Board of Directors: Otsuka Holdings Co., Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
Tatsuo Higuchi
BRD | Director/Board Member | 75 | 07/07/2008 |
Noriko Tojo
BRD | Director/Board Member | 62 | 19/08/2008 |
Yoshiro Matsuo
BRD | Director/Board Member | 65 | 07/07/2008 |
Yukio Matsutani
BRD | Director/Board Member | 76 | 29/02/2016 |
| Director/Board Member | 59 | 29/03/2017 | |
Yuko Makino
BRD | Director/Board Member | 64 | 28/02/2018 |
Ichiro Otsuka
CHM | Chairman | 61 | 28/02/2015 |
Shuichi Takagi
BRD | Director/Board Member | 60 | 28/02/2019 |
Yoshihisa Aoki
BRD | Director/Board Member | 74 | 28/02/2019 |
Makoto Inoue
BRD | Director/Board Member | 67 | 26/03/2020 |
Holdings: Otsuka Holdings Co., Ltd.
| Name | Equities | % | Valuation |
|---|---|---|---|
| 14,857,500 | 2.74% | 1 019 M $ | |
EARTH CORPORATION 23.18% | 5,148,000 | 23.18% | 168 M $ |
| 92,323,712 | 4.82% | 129 M $ | |
| 6,406,200 | 0.34% | 126 M $ | |
THE AWA BANK, LTD. 6.29% | 2,517,000 | 6.29% | 97 M $ |
NICHIBAN CO., LTD. 32.59% | 6,758,000 | 32.59% | 86 M $ |
| 80,857,078 | 5% | 44 M $ | |
| 361,310 | 5.53% | 29 M $ | |
TOHO HOLDINGS CO., LTD. 1.08% | 789,800 | 1.08% | 24 M $ |
| 1,160,494 | 0.54% | 23 M $ |
Company details: Otsuka Holdings Co., Ltd.
Otsuka Holdings Co., Ltd.
Shinagawa Grand Central Tower, 12/F
108-8241, Tokyo
+
https://www.otsuka.com/jp/
Generic Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.77% | +7.88% | +44.87% | +171.39% | 34.11B | |
| +0.72% | +4.31% | +10.31% | +91.37% | 47.36B | |
| +2.48% | +4.24% | +304.53% | +1,459.52% | 12.47B | |
| -0.30% | +1.24% | -8.04% | +51.98% | 11.73B | |
| -0.15% | +2.77% | +2.43% | +97.72% | 10.11B | |
| +10.00% | +12.69% | +81.00% | +57.10% | 8.76B | |
| +0.44% | +6.48% | +36.50% | +116.98% | 8.16B | |
| -0.91% | -1.95% | +37.60% | -16.14% | 7.18B | |
| +2.11% | +11.42% | +62.31% | +433.69% | 6.84B | |
| -0.56% | -0.34% | +12.29% | +57.82% | 6.46B | |
| Average | +2.06% | +4.48% | +58.38% | +252.14% | 15.32B | |
| Weighted average by Cap. | +2.52% | +4.00% | +49.16% | +226.23% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4578 Stock
- Company Otsuka Holdings Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition